Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life

Journal of Parkinson's Disease

Volumn 2, Issue 3, 2012, Pages 189-198

  Manson, Alice ^a   Stirpe, Paola ^b   Schrag, Anette ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

clinical features; Dyskinesia; epidemiology; treatment

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DOPAMINE RECEPTOR; ETIRACETAM; FIPAMEZOLE; IDAZOXAN; LEVODOPA; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; OLANZAPINE; PARDOPRUNOX; PERAMPANEL; PRAMIPEXOLE; PRELADENANT; QUETIAPINE; ROPINIROLE; SAFINAMIDE; SARIZOTAN;

AGE DISTRIBUTION; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSKINESIA; GENE MUTATION; HUMAN; INCIDENCE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STEREOTAXIC SURGERY; TREATMENT DURATION;

ANTIPARKINSON AGENTS; DISEASE MANAGEMENT; DYSKINESIA, DRUG-INDUCED; HUMANS; INCIDENCE; LEVODOPA; PARKINSON DISEASE; QUALITY OF LIFE; RISK FACTORS;

EID: 84867491675     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2012-120103     Document Type: Review

References (133)

1. Cotzias GC, Papavasiliou PS, & Gellene R (1969) Modification of Parkinsonism chronic treatment with L-dopa. N Engl J Med, 280, 337-345.
2. Schrag A, & Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain, 123, 2297-2305.
3. Nutt JG (1990) Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology, 40, 340-345. (Pubitemid 20099455)
4. Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol, 47(4 Suppl 1), S2-S9, discussion S9-S11.
5. Muenter MD, & Tyce GM (1971) L-dopa therapy of Parkinson's disease: Plasma L dopa concentration, therapeutic response, and side effects. Mayo Clin Proc, 46, 231-239.
6. Manson AJ, Katzenschlager R, Hobart J, & Lees AJ (2001) High dose naltrexone for dyskinesias induced by levodopa. J Neurol Neurosurg Psychiatry, 70(4), 554-556. (Pubitemid 32269702)
7. Nutt JG (2000) Clinical pharmacology of levodopa-induced dyskinesia. Ann Neurol, 47(4 Suppl 1), S160-S164; discussion S164-S166
8. Durif F (1999) Treating and preventing levodopa-induced dyskinesias: Current and future strategies. Drugs Aging, 14(5), 337-345. (Pubitemid 29213774)
9. Mones RJ, Elizan TS, & Siegel G (1970) L-dopa induced dyskinesias in 152 patients with Parkinson's disease. Trans Am Neurol Assoc, 95, 286-287.
10. Murphy MJ (1979) L-dopa induced dyskinesias in asymmetrical parkinsonism. Acta Neurol Latinoam, 25, 47-52.
11. Marconi R, Lefebvre-Caparros D, Bonnet AM,Vidailhet M, Dubois B, & Agid Y (1994) Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord, 9(1), 2-12. (Pubitemid 24022609)
12. Muenter MD, Sharpless NS, Tyce GM, & Darley FL (1977) Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. Mayo Clin Proc, 52, 163.
13. LeWitt PA (1998) Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. Mov Disord, 13, 731-734.
14. Bozi M, & Bhatia KP (2003) Paroxysmal exercise-induced dystonia as a presenting feature of young-onset Parkinson's disease. Mov Disord, 18(12), 1545-1547. (Pubitemid 38035383)
15. Ahlskog JE,&MuenterMD(2001) Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord, 16, 448-458. (Pubitemid 36041148)
16. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, & Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord, 22(10), 1379-1389. (Pubitemid 47280623)
17. Vitale C, Pellecchia MT, Grossi D, Fragassi N, Cuomo T, Di Maio L, & Barone P (2001) Unawareness of dyskinesias in Parkinson's and Huntington's diseases. Neurol Sci, 22, 105-106. (Pubitemid 33622099)
18. Barbeau A (1980) High level levodopa therapy in severly akinetic Parkinsonism patients: Twelve years later. In: Rinne VK KM, Stamm G (ed) Parkinson's disease: Current progress, problems and management. Elsevier, Amsterdam, p 229-239.
19. Parkinson study group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson study group. Ann Neurol, 39, 37-45.
20. Poewe WH, Lees AJ, & SternGM(1986) Low-dose L-dopa therapy in Parkinson's disease: A 6-year follow-up study. Neurology, 36, 1528-1530. (Pubitemid 17175783)
21. Blanchet PJ, Allard P, Gregoire L, Tardif F, & Bedard PJ (1996) Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci, 23, 189-193. (Pubitemid 26302745)
22. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G,Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, & Watts A (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Arch Neurol, 61, 1044-1053. (Pubitemid 38915945)
23. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, & Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med, 342, 1484-1491. (Pubitemid 30318272)
24. Ĺopez IC, Ruiz PJ, Del Pozo SV, & Bernardos VS (2010) Motor complications in Parkinson's disease: Ten year follow-up study. Mov Disord, 25(16), 2735-2739.
25. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, & Lang AE (2007) Ten year follow up of Parkinson's disease patients randomised to initial therapy with ropinirole or levodopa. Mov Disord, 22, 2409-2417. (Pubitemid 351155989)
26. Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, & Williamson PM (2005) Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Mov Disord, 20(2), 190-199. (Pubitemid 40361122)
27. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, Ang LC, Senthilselvan A, & Hornykiewicz O (2002) Clinical-pathological study of levodopa complications. Mov Disord, 17(2), 289-296. (Pubitemid 36041297)
28. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, & Lees AJ; Parkinson's Disease Research Group of the United Kingdom (2008) Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology, 71(7), 474-480.
29. Van Gerpen JA (2006) Dopa-responsive dystonic camptocormia. Neurology, 66(11), 1779. (Pubitemid 43964648)
30. Linasazoro G (2005) New ideas on the origin of L-dopainduced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci, 26(8), 391-397.
31. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, & Lang AE (2006) Development of dyskinesia in a 5 year trial of ropinirole and L-dopa. Mov Disord, 21, 1844-1850. (Pubitemid 44848929)
32. Fahn S; and the Parkinson Study Group (2000) Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4), IV37-IV42. (Pubitemid 41437719)
33. Grandas F, Galiano ML, & Tabernero C (1999) Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol, 246, 1127-1133. (Pubitemid 30021235)
34. Kostíc VS, Marinkovíc J, Svetel M, Stefanova E, & Przedborski S (2002) The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol, 9(1), 9-14.
35. Onofrj M, Paci C, & Thomas A (1998) Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease. J Neurol Neurosurg Psychiatry, 65, 605-606. (Pubitemid 28438907)
36. Baas H (2000) Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors. J Neurol, 247(Suppl 4), IV/12-16.
37. Denny AP,&BehariM(1999) Motor fluctuations in Parkinson's disease. J Neurol Sci, 165, 18-23. (Pubitemid 29298075)
38. Kumar N, Van Gerpen JA, Bower JH, & Ahlskog JE (2005) Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disor, 20, 342-366.
39. Ku S, & Glass GA (2010) Age of Parkinson's disease onset as a predictor for the development of dyskinesia. Mov Disord, 25(9), 1177-1182.
40. Kostic V, Przedborski S, Flaster E,&Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology, 41, 202-205.
41. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, & Quinn N(1998)Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality.Mov Disord, 13, 885-894. (Pubitemid 28517664)
42. Quinn N, Critchley P, & Marsden CD (1987) Young onset Parkinson's disease. Mov Disord, 2, 73-79.
43. Papapetropoulos S, Argyriou AA, Ellul J, & Chroni E (2004) Comparison of motor fluctuations and L-dopainduced dyskinesias in patients with familial and sporadic Parkinson's disease. Eur J Neurol, 11(2), 115-119. (Pubitemid 38230787)
44. Khan NL, Katzenschlager R,Watt H, Bhatia KP,WoodNW, Quinn N, & Lees AJ (2004) Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurologu, 62(7), 1224-1226. (Pubitemid 38456528)
45. Khan NL, Graham E, Critchley P, Schrag AE, Wood NW, Lees AJ, Bhatia KP, Quinn N (2005) Parkin disease: A phenotypic study of a large case series. Brain, 126, 1279-1292.
46. Dekker M, Bonifati V, van Swieten J, Leenders N, Galjaard RJ, Snijders P, Horstink M, Heutink P, Oostra B,&van Duijn C (2003) Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov Disord, 18(7), 751-757. (Pubitemid 36939969)
47. Nishioka K, Kefi M, Jasinska-Myga B, Wider C, Vilariño-G̈uell C, Ross OA, Heckman MG, Middleton LT, Ishihara-Paul L, Gibson RA, Amouri R, Ben Yahmed S, Ben Sassi S, Zouari M, El Euch G, Farrer MJ, & Hentati F (2010) A comparative study of LRRK2, PINK1 and genetically undefined familial. Parkinson's disease, 81(4) 391-395.
48. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, & Wood NW (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: Clinical, pathological, olfactory and functional imaging and genetic data. Brain, 128, 2786-2796. (Pubitemid 41746633)
49. Marras C, Scḧule B, Munhoz RP, Rogaeva E, Langston JW, Kasten M, Meaney C, Klein C,Wadia PM, Lim SY, Chuang RS, Zadikof C, Steeves T, Prakash KM, de Bie RM, Adeli G, Thomsen T, Johansen KK, Teive HA, Asante A, Reginold W, & Lang AE (2011) Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurolgy, 77(4), 325-333.
50. Lohmann E, Thobois S, Lesage S, Broussolle E, du Montcel ST, Ribeiro MJ, Remy P, Pelissolo A, Dubois B, Mallet L, Pollak P, Agid Y, & Brice A, French Parkinson's Disease Genetics Study Group (2009) A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology, 72(2), 110-116.
51. Oliveri RL, Annesi G, Zappia M, Civitelli D, Montesanti R, Branca D, Nicoletti G, Spadafora P, Pasqua AA, Cittadella R, Andreoli V, Gambardella A, Aguglia U, & Quattrone A (2001) Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 2, 53(7), 142530.
52. Wang J, Liu ZL, & Chen B (2001) Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease. Neurosci Lett, 308(1), 21-24. (Pubitemid 32607671)
53. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, & Drozdzik M (2008) The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease levodopa treatment response, and complications. Pharmacogenet Genomics, 18(9), 815-821.
54. Strong JA, Dalvi A, Revilla FJ, Sahay A, Samaha FJ,Welge JA, Gong J, Gartner M, Yue X,&Yu L (2006) Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord, 21(5), 654-659. (Pubitemid 43792746)
55. Molchadski I, Korczyn AD, Cohen OS, Katzav A, Nitzan Z, Chapman J,&Hassin-Baer S (2001) The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. Acta Neurol Scand, 123(2), 117-121.
56. Foltynie T, Cheeran B, Williams-Gray CH, Edwards MJ, Schneider SA, Weinberger D, Rothwell JC, Barker RA, & Bhatia KP (2009) BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatr, 80(2), 141-144.
57. Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Cir̀o-Candiano IC, Gambardella A, & Quattrone A (2005) Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease:Anexploratory study. Arch Neurol, 62(4), 601-605. (Pubitemid 40489893)
58. Lyons KE, Hubble JP, Troster AI, Pahwa R, & Koller WC (1998) Gender differences in Parkinson's disease. Clin Neuropharmacol, 21, 118-121. (Pubitemid 28152962)
59. Sharma JC, Macnamara L, Hasoon M, Vassallo M, & Ross I (2006) Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade). Parkinsonism Relat Disord, 12(8), 499-505. (Pubitemid 44793116)
60. Kipfer S, Stephan MA, Scḧupbach WM, Ballinari P, & Kaelin-Lang A (2011) Resting tremor in Parkinson disease: A negative predictor of levodopa-induced dyskinesia. Arch Neurol, 8, 1037-1039.
61. Manson AJ, Brown P, O'Sullivan JD, Asselman P, Buckwell D, Lees AJ (2000) An ambulatory dyskinesia monitor. J Neurol Neurosurg Psychiatry, 68, 196-201. (Pubitemid 30245843)
62. Goetz CG, Damier P, Hicking C, Laska E,M̈uller T, Olanow CW, Rascol O,&Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebocontrolled trial. Mov Disord, 22(2), 179-186. (Pubitemid 46374758)
63. Colosimo C, Mart́nez-Mart́n P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, & Goetz CG (2010) Task force report on scales to assess dyskinesia in Parkinson's disease critique and recommendations. Mov Disord, 25(9), 1131-1142.
64. Goetz CG, Nutt JG, & Stebbins GT (2008) The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile. Mov Disord, 23(16), 2398-2403.
65. Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ,&Hobart J (2007) Quantifying the impact of dyskinesias in PD: The PDYS-26:Apatient-based outcome measure. Neurology, 69(6), 555-563. (Pubitemid 47357262)
66. OlanowCW, Obeso JA(2000) Preventing levodopa-induced dyskinesias. Ann Neurol, 47, S167-S176; discussion S176-S168.
67. Lees AJ, & Stern GM (1981) Sustained bromocriptine therapy in previously untreated patients with Parkinsons disease. J Neurol Neurosurg Psychiatry, 44, 1020-1023. (Pubitemid 12250452)
68. Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, & Poewe W et al. (2010) Randomized, doubleblind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord, 25, 2542-2549.
69. Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, & Earl NL; 228 Study Investigators (2010) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord, 25, 858-866.
70. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, & Montastruc JL; PKDS009 Study Group (2004) The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs, 18(11), 733-746. (Pubitemid 39243565)
71. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, & Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease. Mov Disord, 26(Suppl), 3S2-3S4.
72. Katzenschlager R, & Lees AJ (2002) Treatment of Parkinson's disease: Levodopa as the first choice. J Neurol, 249(Suppl 2), II19-24. (Pubitemid 35025130)
73. Chase TN (1998) The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs, 55(Suppl 1), 1-9. (Pubitemid 28051032)
74. Nutt JG (2007) Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? Mov Disord, 22(1), 1-9. (Pubitemid 46382666)
75. HadjTahar A, Grondin R, Gŕegoire L, Calon F, Di PaoloT,& B́edard PJ (2003) New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable. Adv Neurol, 91, 51-64.
76. Fabbrini G, Di Stasio F, Bloise M, & Berardelli A (2010) Soluble and controlled-release preparations of levodopa: Do we really need them? J Neurol, 257(Suppl 2), S292-S297.
77. Gottwald MD, & Aminoff MJ (2011) Therapies for Dopaminergic-Induced Dyskinesia in Parkinson Disease. Ann Neur, 69, 919-927.
78. Manson AJ, Turner K, & Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients. Mov Disord, 17(6), 1235-1241. (Pubitemid 36041337)
79. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, & Lees AJ (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Mov Disord, 20(2), 151-157. (Pubitemid 40361117)
80. Nilsson D, Nyholm D, & Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand, 104(6), 343-348. (Pubitemid 33107378)
81. Antonini A, Bondiolotti G, Natuzzi F, & Bareggi SR (2010) Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol, 20(10), 683-687.
82. Lees AJ (1993) Dopamine agonists in Parkinson's disease: A look at apomorphine. Fundam Clin Pharmacol, 7, 1-128.
83. Devos D, French DUODOPA Study Group (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord, 24, 993-1000.
84. Antonini A, Isaias IU, Rodolfi G, Landi A, Natuzzi F, Siri C, Pezzoli G (2011) A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol, 258(4), 579-585.
85. Eggert K, Schrader C, Hahn M, Stamelou M, R̈ussmann A, Dengler R, Oertel W, & Odin P (2008) Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol, 31(3), 151-166. (Pubitemid 351787111)
86. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, & Pezzoli G (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord, 22(8), 1145-1149. (Pubitemid 47067225)
87. Urban PP, Wellach I, Faiss S, Layer P, Rosenkranz T, Knop K, & Weis J (2010) Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord, 25(11), 1748-1752.
88. Cenci MA, Ohlin KE, & Odin P (2011) Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol Disord Drug Targets, 10, 670-684.
89. Rascol O (2000) Medical treatment of levodopa-induced dyskinesias. Ann Neurol, 47, S179-S188. (Pubitemid 30192024)
90. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, MouradianMM,&ChaseTN(1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology, 50, 1323-1326. (Pubitemid 28240346)
91. Snow BJ, Macdonald L, McAuley D, & Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study. Clin Neuropharmacol, 23(2), 82-85. (Pubitemid 30212217)
92. da Silva-J́unior FP, Braga-Neto P, Sueli Monte F,&de Bruin VM (2005) Amantadine reduces the duration of levodopainduced dyskinesia: A randomized, double-blind, placebocontrolled study. Parkinsonism Relat Disord, 11(7), 449-452. (Pubitemid 41526996)
93. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, & Poewe W (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord, 25(10), 1357-1363.
94. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, & Bonuccelli U (2001) Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study. Mov Disord, 16(3), 515-520. (Pubitemid 36041158)
95. Crosby NJ, Deane KH, Clarke CE (2003) Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev, CD003467.
96. Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, HisanagaK,KawamuraT; Amantadine Study Group (2010) Amantadine for dyskinesias in Parkinson's disease: A randomized controlled trial. PLoS One, 5(12), 15298.
97. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, & Rascol O (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology, 62(3), 381-388. (Pubitemid 38200847)
98. Bennett JP Jr, Landow ER, Dietrich S, Schuh LA (1994) Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord, 9(4), 409-414. (Pubitemid 24238368)
99. Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, & Scoppetta C (1998) Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand, 97(5), 295-299. (Pubitemid 28191920)
100. Manson AJ, Schrag A, & Lees AJ (2000) Low-dose olanzapine for levodopa induced dyskinesias. Neurology, 55, 795-799.
101. Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ (2004) Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: A double blind cross over study. J Neurol Neurosurg Psychiatry, 5(2), 295-297. (Pubitemid 38183542)
102. Lyons KE, & Pahwa R (2006) Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopainduced dyskinesia. Clin Neuropharmacol, 29(3), 148-153. (Pubitemid 44503893)
103. Stathis P,Konitsiotis S,Tagaris G,&Peterson D;VALID-PD Study Group (2010) Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord, 26(2), 264-270.
104. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, & Wolski K (2011) Preladenant in patients with Parkinson's disease and motor fluctuations: A phase 2, double-blind, randomised trial. Lancet Neurol, 10(3), 221-229.
105. Schapira AH (2010) Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother, 11(13), 2261-2268.
106. Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR,&Brotchie JM (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord, 18(8), 872-883. (Pubitemid 37021161)
107. Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, & Agid Y (2001) Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord, 16(4), 708-713. (Pubitemid 36040852)
108. Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E,&OertelW(2010) German Competence Network on Parkinson's Disease. Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. Mov Disord, 25(7) 896-890.
109. Bronzova J, Sampaio C, Hauser RA, Lang AE, Rascol O, Theeuwes A, van deWitte SV,&van ScharrenburgG(2010) Bruegel Study Group Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord, 25(6), 738-746.
110. Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, &PerezXA(2009) Multiples role for nicotine in Parkinson's disease. Biochem Pharmacol, 78, 677-685.
111. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Gasparini F, Hariry S, Johns D, & a Gomez-Mancilla B (2010) AFQ056 treatment of severe levodopa-induced dyskinesias: proof of concept study. Mov Disord, 25(Suppl2), S290.
112. Gŕegoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B,& Di Paolo T (2011) The acute anti parkinsonian and anti dyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord, 17(4), 270-276.
113. Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A, Marks WJ Jr, Moro E, Vitek JL, Weaver FM, Gross RE, & DeLong MR (2011) Deep brain stimulation for Parkinson disease: An expert consensus and review of key issues. Arch Neurol, 68(2), 165.
114. SankarT,&LozanoAM(2011) Surgical approach to l-dopainduced dyskinesias. Int Rev Neurobiol, 98, 151-171.
115. Pilitsis JG, Metman LV, Toleikis JR, Hughes LE, Sani SB,& Bakay RA (2008) Factors involved in long-term efficacy of deep brain stimulation of the thalamus for essential tremor. J Neurosurg, 109(4), 640-646.
116. Krach P, Batin A, Van Blercom N, Chabardas S, Fraix V, Ardouin C, Limousin PD, Benazzouz A, LeBas JF, Benabid AL,&Pollak P (2003) Five year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinsin's disease. N Enngl J Med, 349, 1923-1934.
117. Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A, & Freund HJ (2004) Long-term results of bilateral pallidal stimulation in Parkinson's disease. Ann Neurol, 55(6), 871-875. (Pubitemid 38702583)
118. Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, HollowayK, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, & Reda DJ; CSP 468 Study Group (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med, 362(22), 2077-2091.
119. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, Rothlind J, Sagher O, Reda D, Moy CS, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, HollowayK, Samii A, Horn S, Bronstein J, Stoner G, Heemskerk J, & Huang GD; CSP 468 Study Group (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: A randomized controlled trial. JAMA, 301(1), 63-73.
120. Rascol O, Lozano A, Stern M, & Poewe W (2011) Milestones in Parkinson's disease therapeutics. Mov Disord, 26(6), 1072-1082.
121. Hamani C, Neimat J,&LozanoAM(2006) Deep brain stimulation for the treatment of Parkinson's disease. J Neural Transm Suppl, 70, 393-399. (Pubitemid 44622228)
122. Contarino MF, Daniele A, Sibilia AH, Romito LM, Bentivoglio AR, Gainotti G, & Albanese A (2007) Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry, 78(3), 248-252. (Pubitemid 46579660)
123. Saint-Cyr JA, Tŕepanier LL, Kumar R, Lozano AM,&Lang AE (2000) Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain, 123, 2091-2108.
124. Ḧalbig TD, Tse W, Frisina PG, Baker BR, Hollander E, Shapiro H, Tagliati M, Koller WC, & Olanow CW (2009) Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol, 16(4), 493-497.
125. Smeding HM, Speelman JD, Koning-Haanstra M, Schuurman PR, Nijssen P, van Laar T, & Schmand B (2006) Neuropsychological effects of bilateral STN stimulation in Parkinson disease: A controlled study. Neurology, 66(12), 1830-1836. (Pubitemid 44049811)
126. Koch G (2010) rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: Searching for effectiv cortical targets Restorative. Neurology and Neuroscience, 28, 561-568.
127. Chapuis S, Ouchchane L, Metz O, Gerbaud L, & Durif F (2005) Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord, 20, 224-223.
128. Steiger MJ, Quinn NP, & Marsden CD (1991) Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease [letter]. Mov Disord, 6, 91-92.
129. DamianoAMMM,William MK, SnyderCF CF, LeWitt PA, & Richter RR (2000) Evaluation of a measurement strategy for Parkinson's disease: Patient health-related quality of life. Quality of Life Research, 9, 87-100. (Pubitemid 30670652)
130. Siderowf A, Ravina B, & Glick HA (2002) Preferencebased quality-of-life in patients with Parkinson's disease. Neurology, 59, 103-108. (Pubitemid 34742802)
131. Pechevis M, & Vieregge P (2001) Direct and indirect costs of Parkinson's Disease and L-dopa induced dyskinesias: A prospective European study. Parkinsonism Relat Disord, 7(suppl), 106.
132. Marras C, Lang A, Krahn M, Tomlinson G, & Naglie G (2004) Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. Mov Disord, 19, 22-28. (Pubitemid 38559616)
133. Amanzio M, Monteverdi S, Giordano A, Soliveri P, Filippi P, & Geminiani G (2010) Impaired awareness of movement disorders in Parkinson's disease. Brain Cogn, 72(3), 337-346.